Skip to content

In the BioHarmony Drug Report Database

Certolizumab pegol

Cimzia (certolizumab pegol) is an antibody pharmaceutical. Certolizumab pegol was first approved as Cimzia on 2008-04-22. It is used to treat ankylosing spondylitis, crohn disease, psoriatic arthritis, and rheumatoid arthritis in the USA. It has been approved in Europe to treat rheumatoid arthritis. The pharmaceutical is active against tumor necrosis factor.
Trade Name Cimzia
Common Name Certolizumab pegol
Indication ankylosing spondylitis, crohn disease, psoriatic arthritis, rheumatoid arthritis
Drug Class Monoclonal antibodies: humanized, immunomodulating; PEGylated compounds
Certolizumab pegol
Get full access now